WASHINGTON, DC (December 10, 2020) — The Association for Accessible Medicines and its members look forward to working with President-elect Biden’s U.S. Trade Representative (USTR)-designee Katherine Tai to ensure that U.S. trade policy promotes the proper balance between pharmaceutical innovation and off-patent competition that expands patient access to medicines and reduces health care costs.
USTR-designee Tai was an instrumental leader in ensuring that the U.S.-Mexico-Canada Agreement reflected this balance, and her nomination is a clear signal of the importance of this policy perspective in the Biden-Harris Administration.
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 20 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.